Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.58 |
| ▸ | HINT1 | P49773 | 5/20 | 0.58 |
| ▸ | NT5E | P21589 | 1/20 | 0.55 |
| ▸ | STING1 | Q86WV6 | 4/20 | 0.55 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.55 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.55 |
| ▸ | GSK3A | P49840 | 2/20 | 0.52 |
| ▸ | RPS6KA3 | P51812 | 2/20 | 0.52 |
| ▸ | MAPK14 | Q16539 | 2/20 | 0.52 |
| ▸ | TGM2 | P21980 | 1/20 | 0.51 |
| ▸ | PNP | P00491 | 1/20 | 0.50 |
| ▸ | HPGD | P15428 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23200375 | 1.00 | TAAR1 (0.58) | TAAR1HINT1NT5ESTING1PDE3B | |
| SCHEMBL23200376 | 1.00 | TAAR1 (0.58) | TAAR1HINT1NT5ESTING1PDE3B | |
| SCHEMBL800400 | 1.00 | TAAR1 (0.58) | TAAR1HINT1NT5ESTING1PDE3B | |
| SCHEMBL23710671 | 1.00 | TAAR1 (0.58) | TAAR1HINT1NT5ESTING1PDE3B | |
| SCHEMBL800874 | 1.00 | TAAR1 (0.58) | TAAR1HINT1NT5ESTING1PDE3B | |
| SCHEMBL23710670 | 1.00 | TAAR1 (0.58) | TAAR1HINT1NT5ESTING1PDE3B | |
| SCHEMBL7535718 | 0.92 | HINT1 (0.58) | TAAR1HINT1NT5ESTING1PDE3B | |
| SCHEMBL7541561 | 0.89 | TAAR1 (0.56) | TAAR1HINT1NT5ESTING1PDE3B | |
| SCHEMBL7111072 | 0.89 | HINT1 (0.55) | TAAR1HINT1NT5ESTING1PDE3B | |
| SCHEMBL2424287 | 0.89 | HINT1 (0.55) | TAAR1HINT1NT5ESTING1PDE3B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250207131-A1 | MODIFIED RNA AGENTS WITH REDUCED OFF-TARGET EFFECT | ALNYLAM PHARMACEUTICALS, INC. (US) | 2025-06-26 | — | — | US | disclosed |
| US-12275938-B2 | Modified RNA agents with reduced off-target effect | ALNYLAM PHARMACEUTICALS, INC. (US) | 2025-04-15 | — | — | US | disclosed |
| US-12247203-B2 | Modified RNA agents with reduced off-target effect | ALNYLAM PHARMACEUTICALS, INC. | 2025-03-11 | — | — | US | disclosed |
| US-20220290145-A1 | Modified RNA Agents with Reduced Off-Target Effect | ALNYLAM PHARMACEUTICALS, INC. (US) | 2022-09-15 | — | — | US | disclosed |
| US-20210238595-A1 | MODIFIED RNA AGENTS WITH REDUCED OFF-TARGET EFFECT | ALNYLAM PHARMACEUTICALS, INC. (US) | 2021-08-05 | — | — | US | disclosed |
| EP-2623104-A1 | Substituted nucleoside and nucleotide analogs | Alios Biopharma, Inc. (US) | 2013-08-07 | — | — | EP | disclosed |
| WO-2012040126-A1 | SUBSTITUTED NUCLEOTIDE ANALOGS | ALIOS BIOPHARMA, INC. (US) | 2012-03-29 | — | — | WO | disclosed |
| US-20120070411-A1 | SUBSTITUTED NUCLEOTIDE ANALOGS | ALIOS BIOPHARMA, INC. (US) | 2012-03-22 | — | — | US | disclosed |
| US-20120070411-A1 | SUBSTITUTED NUCLEOTIDE ANALOGS | ALIOS BIOPHARMA, INC. (US) | 2012-03-22 | — | — | US | disclosed |
| US-20120070411-A1 | SUBSTITUTED NUCLEOTIDE ANALOGS | ALIOS BIOPHARMA, INC. (US) | 2012-03-22 | — | — | US | disclosed |
| US-20100249068-A1 | SUBSTITUTED NUCLEOSIDE AND NUCLEOTIDE ANALOGS | ALIOS BIOPHARMA, INC. (US) | 2010-09-30 | — | — | US | disclosed |
| US-20100249068-A1 | SUBSTITUTED NUCLEOSIDE AND NUCLEOTIDE ANALOGS | ALIOS BIOPHARMA, INC. (US) | 2010-09-30 | — | — | US | disclosed |
| WO-2010108140-A1 | SUBSTITUTED NUCLEOSIDE AND NUCLEOTIDE ANALOGS | ALIOS BIOPHARMA, INC. (US) | 2010-09-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120070411-A1 | SUBSTITUTED NUCLEOTIDE ANALOGS | PNP, NTPCR, NUDT1 | TAAR1 3715/4885HINT1 76/4885NT5E 15/4885 |
| US-20100249068-A1 | SUBSTITUTED NUCLEOSIDE AND NUCLEOTIDE ANALOGS | PNP, TYMP, NTPCR | TAAR1 3985/4885HINT1 91/4885NT5E 19/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.